Superior Planning, LLC’s Celldex Therapeutics CLDX Stock Holding History

Superior Planning, LLC’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.88K	Buy	+89	New	+$3.4K	﹤0.01%	1423

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Panagora Asset Management Boston, Massachusetts $33.2B AUM 43.67% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Superior Planning, LLC's CLDX Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Celldex Therapeutics (CLDX) in Q3 2026: 89 shares worth $2.88K. The stake represents ﹤0.01% of the portfolio and ranks #1423 among its holdings.

133 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

Superior Planning, LLC held 89 shares of Celldex Therapeutics worth $2.88K as of Q3 2026.
Celldex Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Celldex Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1423 holding.
133 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.